secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-12-16T23:59:59+00:00
Accession:  0000950170-24-136674
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics appoints Torsten Hombeck as CFO effective Dec 16, 2024
-------------------------------------------------------------------------

- Torsten Hombeck appointed CFO effective Dec 16, 2024; previously served as CFO from Oct 2019 to June 2024.
- Annual base salary of $300,000 with target bonus of up to 100%.
- Dr. Hombeck most recently served as CFO at Aspira Women's Health (June 2023–June 2024).
- No family relationships or transactions with other directors or officers noted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024136674/0000950170-24-136674-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024136674/aktx-20241212.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-136674

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer